EGFR and lung cancer: In 2003 and 2004, targeted therapies for epidermal growth factor receptor (EGFR) alterations in lung cancer, gefitinib and erlotinib were developed and ctDNA offered an easy and potentially quicker route to determine if patients were candidates for these directed therapies.